Recent news on Tenofovir Disoproxil Fumarate

Gilead Sciences counts on Indian pharma companies  -  May 13, 2007
Moneycontrol.com,The agreements entered into since last September cover two drugs, Emtriva (emtricitabine) and Viread (tenofovir disoproxil fumarate), and allows the Indian

Aids drug awaits patent in India  -  May 20, 2007
Gulf Times,According to Alton, Viread (tenofovir disoproxil fumarate) is on its way to becoming the frontrunner drug across Europe for HIV/Aids due to its low toxicity

Aspen to market ARV products  -  Apr 24, 2007
Sunday Times,...key Anti-Retroviral (ARV) products Viread (tenofovir disoproxil fumarate) and Truvada (emtricitabine and tenofovir disoproxil fumarate) in South Africa.

Gilead Sciences: Rapid Growth Expected From New Products  -  Apr 3, 2007
Seeking Alpha,...including the strong uptake of Atripla (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) following its launch in July 2006

Gilead Sciences Announces First Quarter 2007 Financial Results  -  Apr 19, 2007
PharmaLive.com (press release),Sales of Viread(R) (tenofovir disoproxil fumarate) were $160.7 million in the first quarter of 2007, a 16 percent decrease from $191.8 million in the first

Gilead's Atripla, Lower Costs Provide Lift To First Quarter  -  Apr 22, 2007
BioWorld Online,Truvada - the combo HIV drug pairing Gilead's Viread (tenofovir disoproxil fumarate) and Emtriva (emtricitabine), did especially well in Europe.

AbelsonTaylor Expands Account Services with Two New Hires  -  Apr 20, 2007
PharmaLive.com (press release),Dan Lathitham, 31, will manage the agency’s account for Gilead’s Truvada® (emtricitabine and tenofovir disoproxil fumarate) for the treatment of HIV.

Pharma firms find US ally in patent row  -  Mar 27, 2007
Business Standard,The review petition, filed by the US NGO with USPTO, also challenges four key HIV/AIDS drug patents held by Gilead for Tenofovir Disoproxil Fumarate (TDF)

Narrative Review: Antiretroviral Therapy to Prevent the Sexual ...  -  Apr 16, 2007
Annals of Internal MedicineTopical administration of low-dose tenofovir disoproxil fumarate to protect infant macaques against multiple oral exposures of low doses of simian

PUBPAT Takes on Key HIV/AIDS Drug Patents  -  27 Mar 2007
ag-IP-news Agency,5922695, 5935946, 5977089 and 6043230, relate to the drug known generically as Tenofovir Disoproxil Fumarate (TDF), a key weapon in the battle against

Tenofovir-Ritonavir Combination Therapy Linked to Nephrotoxicity ...  -  Mar 5, 2007
DG News..."Tenofovir disoproxil fumarate has been associated with renal toxicity in previous reports," noted Christopher Mathews, MD, director, Owen Clinic,

New HIV listings added to Pharmaceutical Schedule  -  Mar 14, 2007
Scoop.co.nz,Tenofovir disoproxil fumarate, emtricitabine and efavirenz versus fized-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patinets.

HIV market: collaborative combinations  -  Mar 13, 2007
Pharmaceutical Business ReviewGSK's Combivir (lamivudine and zidovudine) or Gilead's Truvada (emtricitabine and tenofovir disoproxil fumarate) are potential candidates for such a

Merck & Co., Inc. To Distribute ATRIPLA™ in Developing Countries  -  Feb 16, 2007
WebWire (press release),Emtricitabine and tenofovir disoproxil fumarate are commercialized by Gilead Sciences under the tradenames Emtriva® and Viread®, respectively.

Merck & Co., Inc. 1 To Distribute ATRIPLA TM in Developing Countries  -  Feb 16, 2007
Business Wire (press release),Emtricitabine and tenofovir disoproxil fumarate are commercialized by Gilead Sciences under the tradenames Emtriva ® and Viread ® , respectively.

Merck & Co., Inc. (1) To Distribute ATRIPLA(TM) in Developing ...  -  Feb 16, 2007
Genetic Engineering News (press release),Emtricitabine and tenofovir disoproxil fumarate are commercialized by Gilead Sciences under the tradenames Emtriva(R) and Viread(R), respectively.

Merck to give 3-in-1 HIV drug overseas  -  Feb 16, 2007
United Press International...and tenofovir disoproxil fumarate 300 mg -- with health authorities in countries that have high concentrations of the infection in their populations.

Gilead Sciences Announces Fourth Quarter and Full Year 2006 ...  -  Feb 1, 2007
PharmaLive.com (press release),...including the strong uptake of Atripla(TM) (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) following its launch in July

Cipla lends support to anti-patent drive  -  Feb 14, 2007
Economic Times,...generic versions of Viread (generic name: tenofovir disoproxil fumarate) in India and other developing countries, including South Africa and Thailand.

Shasun Chemicals to raise Rs 198 mn through warrants issue  -  Jan 3, 2007
Myiris.com,...agreement with Gilead Sciences for the manufacture and sale of a generic version of Tenofovir Disoproxil Fumarate using Gilead`s proprietary technology.

96-Week Data From Gilead’s Study 934 Comparing Viread ® and ...  -  Dec 15, 2006
Business Wire (press release),This study compares a once-daily regimen of Viread ® (tenofovir disoproxil fumarate), Emtriva ® (emtricitabine) and Sustiva ® (efavirenz) to a twice-daily ...

96-Week Data From Gilead's Study 934 Comparing Viread and Emtriva ...  -  Dec 15, 2006
PharmaLive.com (press release),This study compares a once-daily regimen of Viread(R) (tenofovir disoproxil fumarate), Emtriva(R) (emtricitabine) and Sustiva(R) (efavirenz) to a twice-daily ...

Triple nuke combination of AZT/3TC/tenofovir below current ...  -  Dec 17, 2006
Aidsmap,Rey D et al. Virologic response of zidovudine, lamivudine, and tenofovir disoproxil fumarate combination in antiretroviral-naive HIV-1-infected patients. ...

Market Report -- In Play (GILD)  -  Dec 15, 2006
MSN MoneyThe study article, "Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Versus Fixed-Dose Zidovudine/Lamivudine and Efavirenz in Antiretroviral-Naive ...

Gilead Sciences Receives Subpoena from US Department of Justice  -  Dec 7, 2006
American Digital Networks (press release),Francisco requesting documents regarding its marketing and medical education programs for Truvada(R) (emtricitabine and tenofovir disoproxil fumarate), Viread(R ...

Gilead Sciences Receives Subpoena from US Department of Justice  -  Dec 7, 2006
Business Wire (press release),...documents regarding its marketing and medical education programs for Truvada ® (emtricitabine and tenofovir disoproxil fumarate), Viread ® (tenofovir ...

Pharma rivals strike a chord, join hands for product experiments  -  Dec 10, 2006
Economic Times,...arrangement between US-based Gilead Lifescience and about 10 Indian companies for selling its blockbuster AIDS drug tenofovir disoproxil fumarate here, even ...

New HIV drug likely to ease the pain  -  Dec 2, 2006
Mmegi,ARV therapy. Atripla contains 600mg of efavirenz, 200mg of emtricitabine and 300mg of tenofovir disoproxil fumarate. The formulation ...

Result Analysis: Matrix Laboratories net falls 68.65% in Sept qtr  Nov 2, 2006
...has recently signed a licensing agreement with Gilead for the manufacture and sale of a generic version of Tenofovir Disoproxil Fumarate using Gilead`s ... -Myiris.com, Source: Bristol-Myers Squibb Company  Oct 8, 2006
Submit Marketing Authorisation Application for ATRIPLA(TM) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) to European Medicines ... -Yahoo! News (press release) Bristol-Myers Squibb, Gilead Sciences and Merck & Co. Submit ...  Oct 10, 2006
...the submission of a Marketing Authorisation Application (MAA) for ATRIPLA(TM) (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) in ... -Drug Newswire (press release), Shasun signs manufacturing pact with Gilead  Oct 25, 2006
...a non-exclusive licensing agreement with Gilead Sciences for the manufacture and sale of the generic version of Tenofovir Disoproxil Fumarate, using Gilead's ... -Express Pharma, Gilead Sciences Announces Third Quarter 2006 Financial Results  Oct 18, 2006
...be driven primarily by Gilead's HIV product franchise, including the strong performance of Truvada(R) (emtricitabine and tenofovir disoproxil fumarate) and the ... -Genetic Engineering News (press release), Bristol-Myers, Gilead Sciences, Merck Submit Marketing ...  Oct 9, 2006
ATRIPLA is a once-daily single tablet regimen containing 600 mg of efavirenz, 200 mg of emtricitabine, and 300 mg of tenofovir disoproxil fumarate, which has ... -Trading Markets, (PRN) - Arrow Executive to Speak at Philippines' CEO Forum ... [+]  Oct 9, 2006
Submit Marketing Authorisation Application for ATRIPLA(TM) (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) to E ... [+. ... -Bolsamania.com, Bristol-Myers Squibb Company Reports Financial Results for the ...  Oct 26, 2006
...submitted ATRIPLA(TM) (efavirenz 600 mg / emtricitabine 200 mg / tenofovir disoproxil fumarate 300 mg) for regulatory approval in Canada. ... -Yahoo! News (press release) Media Advisory - Gilead Sciences Announces full Availability of ...  Oct 12, 2006
...today announced that Truvada(TM) (emtricitabine/tenofovir disoproxil fumarate), a new once-daily anti-HIV medication for combination theray, has received ... -Canada NewsWire (press release), FDA Approves REYATAZ(R) (atazanavir sulfate) 300 mg Single Capsule ...  Oct 24, 2006
150 mg capsules for: patients who have previously received anti-HIV medicines, patients who will be receiving tenofovir disoproxil fumarate, and patients who ... -Drug Newswire (press release), FDA Approves Bristol-Myers' Reyataz 300 Mg Capsule In Combination ...  Oct 20, 2006
...to be effective in patients, who already underwent treatment with anti-HIV medicines, patients who will be receiving Viread or tenofovir disoproxil fumarate. ... -Trading Markets, Bristol-Myers, Gilead Sciences And Merck Jointly Submit Marketing ...  Oct 9, 2006
...the submission of a Marketing Authorization Application or MAA for ATRIPLA, efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg, to ... -Trading Markets, Reyataz 300 mg Capsules Approved  Oct 24, 2006
150 mg capsules for patients who have previously received anti-HIV medicines, patients who will be receiving tenofovir disoproxil fumarate, and patients who ... -Facts and Comparisons, Bristol-Myers Squibb Receives FDA Approval for New Formulation of ...  Oct 24, 2006
150 mg formulations of Reyataz for people who previously have taken antiretroviral drugs, people who will be taking tenofovir disoproxil fumarate and people ... -Kaiser network.org, Pharma Sector: Few Newsmakers Of The Week - Merck, Novartis, Teva ...  Oct 21, 2006
...found to be effective in patients, who already underwent treatment with anti-HIV medicines, patients who will be receiving Viread (tenofovir disoproxil fumarate ... -Trading Markets, Shasun's Consolidated CRAM Revenue Zooms to Rs 83.1 Cr in Q2Y07  Oct 19, 2006
Sciences Inc. for manufacture and sale of a generic version of Tenofovir Disoproxil Fumarate using Gilead's proprietary technology. The ... -PharmaLive.com (press release), Pre-exposure prophylaxis may need large doses to work  Sep 19, 2006
Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given ... -Aidsmap

TI and Halliburton Gain On Share Repurchase  Sep 22, 2006
Ltd today announced it signed a licensing agreement with Gilead to manufacture and sale a generic version of Tenofovir Disoproxil Fumarate, an anti AIDS therapy ... -123Jump.com

Making prevention work: interventions with gay men  Sep 7, 2006
Findings from a double-blind, randomized, placebo-controlled trial of tenofovir disoproxil fumarate (TDF) for prevention of HIV infection in women. ... -Aidsmap

AIDS drug to cost lower  Sep 3, 2006
For HIV/AIDs patients therefore, who use the tenofovir disoproxil fumarate (generic name) compound, the cost of treatment is set to come down by half. ... -Andhra Cafe

Gilead Sciences Receives Subpoena from US Department of Justice  -  Dec 8, 2006
PharmaLive.com (press release),...programs for Truvada(R) (emtricitabine and tenofovir disoproxil fumarate), Viread(R) (tenofovir disoproxil fumarate) and Emtriva(R) (emtricitabine).

Gilead Sciences Receives Subpoena from US Department of Justice  -  Dec 7, 2006
Business Wire (press release),...programs for Truvada ® (emtricitabine and tenofovir disoproxil fumarate), Viread ® (tenofovir disoproxil fumarate) and Emtriva ® (emtricitabine).

Pharma rivals strike a chord, join hands for product experiments  -  Dec 10, 2006
Economic Times,AIDS drug tenofovir disoproxil fumarate here, even while it is planning to bring its own tenofovir brand called Viread to India at a competitive price.

FDC signs agreement with US-based Akom  -  Nov 13, 2006
Hindu,FDC has also entered into a non-exclusive license agreement with Gilead Sciences Inc, for production and distribution of Tenofovir Disoproxil Fumarate

New HIV drug likely to ease the pain  -  Dec 2, 2006
Mmegi,Atripla contains 600mg of efavirenz, 200mg of emtricitabine and 300mg of tenofovir disoproxil fumarate. The formulation of this new drug was driven by the

Drug-Drug Interactions Clinically Manageable With PREZISTA(TM)  -  Nov 14, 2006
Drug Newswire (press release),...lopinavir/ritonavir, saquinavir/ritonavir, efavirenz, nevirapine, tenofovir disoproxil fumarate; antibiotics such as clarithromycin and ketoconazole;

The year that was  -  Nov 12, 2006
Express Pharma,...a licensing agreement with Gilead Sciences covering manufacturing and marketing of API and formulations containing Tenofovir Disoproxil Fumarate (TDF).



US FDA Grants Traditional Approval for Gilead's Once-Daily HIV ...  Mar 8, 2006
US Food and Drug Administration (FDA) has granted traditional approval status to its once-daily antiretroviral Viread® (tenofovir disoproxil fumarate) and its ... - DG News

Truvada used to prevent AIDS virus infection?  Mar 28, 2006
Truvada is composed of two drugs, namely emtricitabine (Emtriva) and tenofovir disoproxil fumarate (Viread), with each having some, but imperfect effect on ... - Food Consumer

Traditional Approval of Viread and Truvada  Mar 13, 2006
FDA granted traditional approval to two tenofovir DF containing products manufactured by Gilead Sciences, VIREAD (tenofovir disoproxil fumarate) and TRUVADA ... - PharmaLive.com



Gilead's Tenofovir 'Access Program' for Developing Countries: A ...  Feb 7, 2006
Marketed as Viread ® (tenofovir disoproxil fumarate) in the United States, tenofovir was approved by the US Food and Drug Administration more than four years ... - Doctors Without Borders,

AIDS. MSF: MEDICINES DON'T REACH THIRD WORLD  Feb 9, 2006
Marketed as Viread (tenofovir disoproxil fumarate) in the US, tenofovir was approved by the Food and Drug Administration (FDA) 4 years ago, and is now an ... - Agenzia Giornalistica Italia,

AIDS. MSF: MEDICINES DON'T REACH THIRD WORLD  09 Feb 2006
Marketed as Viread (tenofovir disoproxil fumarate) in the US, tenofovir was approved by the Food and Drug Administration (FDA) 4 years ago, and is now an ... - Agenzia Giornalistica Italia

Gilead's Tenofovir ‘Access Program' For Developing Countries: A ...  Feb 7, 2006
Marketed as Viread® (tenofovir disoproxil fumarate) in the United States, tenofovir was approved by the US Food and Drug Administration more than four years ... - Medical News Today

Bristol-Myers Squibb and Gilead Announce Data Supporting ...  Jan 9, 2006
...the fixed-dose combination of Bristol-Myers Squibb's Sustiva(R) (efavirenz) and Gilead's Truvada(R) (emtricitabine and tenofovir disoproxil fumarate) with the ... - Business Wire

Gilead Sciences Announces Fourth Quarter and Full Year 2005 ...  Jan 30, 2006
...primarily by Gilead's HIV product franchise, including the continued strong uptake of Truvada(R) (emtricitabine and tenofovir disoproxil fumarate) since its US ... - Genetic Engineering News

Companies Anticipate Filing New Drug Application in Second Quarter ...  Jan 9, 2006
...of the fixed-dose combination of Bristol-Myers Squibb's Sustiva® (efavirenz) and Gilead's Truvada® (emtricitabine and tenofovir disoproxil fumarate) with the ... - Nieuwsbank (persbericht)

Data Comparing Viread(R) and Emtriva(R) to Combivir(R) as Part of ...  Jan 18, 2006
...publication of 48-week data from a clinical trial (Study 934) comparing a once-daily treatment regimen of Viread(R) (tenofovir disoproxil fumarate), Emtriva(R ... - Genetic Engineering News

Gilead HIV drug combo beats GSK rival in phase III trial  Jan 20, 2006
The clinical trial (Study 934) compared a treatment regimen of Viread (tenofovir disoproxil fumarate), Emtriva (emtricitabine) and Sustiva (efavirenz) to a ... - Pharmaceutical Business Review

Better Treatment for HIV  Jan 18, 2006
Patients taking tenofovir disoproxil fumarate, emtricitabine, and efavirenz once a day were significantly more likely to have lower HIV RNA levels and higher ... - Ivanhoe

NEWS RELEASE  Jan 19, 2006
...of 48-week data from a clinical trial (Study 934) comparing a once-daily treatment regimen of Viread® (tenofovir disoproxil fumarate), Emtriva® (emtricitabine ... - Financial News USA

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional